A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma

被引：92

作者：

Takenaga, M ^{[1
]}

Tamamura, H

Hiramatsu, K

Nakamura, N

Yamaguchi, Y

Kitagawa, A

Kawai, S

Nakashima, H

Fujii, N

Igarashi, R

机构：

[1] St Marianna Univ, Sch Med, Inst Med Sci, Kawasaki, Kanagawa 2168512, Japan

[2] Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan

[3] St Marianna Univ, Sch Med, Dept Microbiol, Kawasaki, Kanagawa 2168511, Japan

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2004年 / 320卷 / 01期

关键词：

B16-BL6; CXCR4; antagonist; melanoma; metastasis; poly D; L-lactic acids; sustained release;

D O I：

10.1016/j.bbrc.2004.05.155

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Biodegradable Poly D,L-lactic acid (PLA, molecular weight: ca. 5000) microcapsules containing a CXCR4 antagonist (4F-benzoyl-TE14011) were prepared (4F-benzoyl-TE14011-PLA), and their anti-metastatic activity was evaluated in mice. A single subcutaneous administration of 4F-benzoyi-TE14011-PLA significantly reduced the number of colonies formed by pulmonary metastasis of B16-BL6 melanoma cells expressing CXCR4. The same dose of 4F-benzoyl-TE14011 in a single or a series of treatments affected little. The substance 4F-benzoyl-TE14011 dose-dependently suppressed B16-BL6 cell growth. In the cells cultured with SDF-1, a more potent suppression was observed. 4F-Benzoyl-TE14011 was rapidly released from 4F-benzoyl-TE14011-PLA for an initial period, both in vitro and in vivo. A steady release was thereafter observed. Therefore, this drug release profile might contribute to prevention of melanoma metastasis at the steps involving the migration and cell growth. These results also show that a sustained drug release formulation could be a useful drug delivery system for CXCR4 antagonists. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：226 / 232

页数：7

共 37 条

[1] The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J].

Bleul, CC ;

Farzan, M ;

Choe, H ;

Parolin, C ;

ClarkLewis, I ;

Sodroski, J ;

Springer, TA .

NATURE, 1996, 382 (6594) :829-833

[2] Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells [J].

Burger, M ;

Glodek, A ;

Hartmann, T ;

Schmitt-Gräff, A ;

Silberstein, LE ;

Fujii, N ;

Kipps, TJ ;

Burger, JA .

ONCOGENE, 2003, 22 (50) :8093-8101

[3]

Chandy T, 2000, J MICROENCAPSUL, V17, P625

[4] THE CD4 (T4) ANTIGEN IS AN ESSENTIAL COMPONENT OF THE RECEPTOR FOR THE AIDS RETROVIRUS [J].

DALGLEISH, AG ;

BEVERLEY, PCL ;

CLAPHAM, PR ;

CRAWFORD, DH ;

GREAVES, MF ;

WEISS, RA .

NATURE, 1984, 312 (5996) :763-767

[5] The therapeutic potential of CXCR4 antagonists in the treatment of HIV [J].

Fujii, N ;

Nakashima, H ;

Tamamura, H .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (02) :185-195

[6]

GERMINDER H, 2001, J IMMUNOL, V167, P4747

[7] Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 [J].

Hatse, S ;

Princen, K ;

Bridger, G ;

De Clercq, E ;

Schols, D .

FEBS LETTERS, 2002, 527 (1-3) :255-262

[8] Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers [J].

Hendrix, CW ;

Flexner, C ;

MacFarland, RT ;

Giandomenico, C ;

Fuchs, EJ ;

Redpath, E ;

Bridger, G ;

Henson, GW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1667-1673

[9]

Huang YY, 2001, J MICROENCAPSUL, V18, P457

[10] A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity [J].

Ichiyama, K ;

Yokoyama-Kumakura, S ;

Tanaka, Y ;

Tanaka, R ;

Hirose, K ;

Bannai, K ;

Edamatsu, T ;

Yanaka, M ;

Niitani, Y ;

Miyano-Kurosaki, N ;

Takaku, H ;

Koyanagi, Y ;

Yamamoto, N .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :4185-4190

← 1 2 3 4 →